+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-a4ß7 Integrin Monoclonal Antibody Market by Indication, Administration Route, Line of Therapy, Distribution Channel, Patient Age Group, Dosage Form - Global Forecast 2025-2030- Product Image
Anti-a4ß7 Integrin Monoclonal Antibody Market by Indication, Administration Route, Line of Therapy, Distribution Channel, Patient Age Group, Dosage Form - Global Forecast 2025-2030- Product Image
New

Anti-a4ß7 Integrin Monoclonal Antibody Market by Indication, Administration Route, Line of Therapy, Distribution Channel, Patient Age Group, Dosage Form - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6118069
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The anti-α4β7 integrin monoclonal antibody class has emerged as a transformative force in the management of gastrointestinal inflammatory disorders, offering targeted immunomodulation that addresses critical unmet needs. As scientific understanding of integrin-mediated lymphocyte trafficking deepens, these therapies are redefining clinical standards for Crohn’s Disease, Ulcerative Colitis and other colonic conditions. In this context, a systematic exploration of the therapeutic landscape is imperative to equip stakeholders with the knowledge required to navigate an increasingly sophisticated market environment.

This report establishes a comprehensive framework that outlines key clinical developments, regulatory milestones, and pharmaceutical innovations influencing the trajectory of anti-α4β7 integrin treatments. By examining multi-dimensional factors-ranging from molecular design and patient stratification to distribution mechanisms and reimbursement dynamics-this introduction sets the stage for a holistic analysis. It positions the reader to appreciate the interplay between scientific progress and commercial viability, illuminating how these agents are poised to reshape standard care pathways and deliver transformative outcomes for patients worldwide.

Unveiling a Paradigm Shift in Gastrointestinal Disease Management through Anti-α4β7 Integrin Monoclonal Antibody Innovations

The landscape of gastrointestinal immunotherapy is undergoing a paradigm shift driven by breakthroughs in monoclonal antibody engineering, evolving regulatory approaches, and intensified competition among biopharma innovators. Recent approval of next-generation agents has expanded the therapeutic armamentarium, catalyzing a ripple effect across clinical practice guidelines. As a result, prescribers are increasingly tailoring treatment regimens to individual disease phenotypes, harnessing the precision of α4β7 blockade to optimize efficacy while managing safety profiles.

Concurrently, payers are recalibrating reimbursement frameworks to balance budgetary constraints with the value of targeted therapies, prompting novel pricing models and outcomes-based agreements. This shift has spurred deeper collaboration between manufacturers and healthcare ecosystems, with digital health platforms facilitating remote monitoring, adherence support and real-world evidence generation. Taken together, these elements are redefining stakeholder expectations and establishing a new benchmark for patient-centric care in inflammatory bowel diseases.

Analyzing the Multifaceted Implications of New United States Tariffs on Anti-α4β7 Integrin Monoclonal Antibody Supply Chains

The introduction of new tariff measures in the United States effective 2025 carries significant implications for the supply chain and commercial strategies of anti-α4β7 integrin monoclonal antibody developers. Raw material costs, particularly for advanced recombinant proteins and specialty excipients, are subject to elevated import duties, demanding proactive mitigation by manufacturers. Consequently, organizations must reassess sourcing strategies, explore alternative suppliers, and optimize logistics to preserve margins without compromising product integrity.

These trade policy adjustments also reverberate through contract manufacturing relationships, influencing lead times and capacity planning. Forward-thinking companies are renegotiating procurement terms, investing in localized production capabilities, and refining inventory management to mitigate exposure to tariff-induced volatility. Meanwhile, regulatory liaison activities have intensified as stakeholders seek clarity on duty classifications and exemptions. Cumulatively, these responses underscore the necessity for agility in operational frameworks and a robust understanding of evolving trade environments.

Delineating Critical Market Segments to Illuminate Therapeutic Adoption Patterns for Anti-α4β7 Integrin Monoclonal Antibodies

Insights into market segmentation reveal diverse adoption patterns shaped by clinical indication, administration route, line of therapy, distribution channel, patient age group, and dosage form. When examining clinical indications, the spectrum covers Crohn’s Disease, Indeterminate Colitis, Microscopic Colitis and Ulcerative Colitis, with Crohn’s further classified into colonic, ileal and ileocolonic presentations and Ulcerative Colitis encompassing left-sided colitis, pancolitis and proctitis. Administration routes influence prescriber preferences and patient adherence, as intravenous infusion protocols contrast with the convenience of subcutaneous injections.

Line of therapy segmentation underscores the evolving role of these antibodies from first-line interventions through second-line applications and into third-line and beyond, indicating shifting treatment algorithms. Distribution channels shape access dynamics, reflecting the distinct roles of hospital pharmacies-both inpatient and outpatient-alongside retail pharmacies, encompassing chain and independent outlets, and specialty pharmacies differentiated by hospital affiliation and standalone operations. Patient demographics, spanning adult, geriatric and pediatric cohorts, further modulate clinical outcomes and support requirements. Finally, dosage form preferences drive innovations in autoinjectors, prefilled syringes and single-dose vials, highlighting the interplay between user experience, safety protocols and therapeutic efficiency.

Comparative Regional Dynamics Shaping the Adoption of Anti-α4β7 Integrin Monoclonal Antibody Treatments Across Global Markets

Regional analysis highlights distinct trajectories in the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, established reimbursement infrastructures and a high concentration of research centers accelerate clinical adoption, while ongoing health policy debates shape coverage pathways and patient affordability. Transitioning to Europe, Middle East & Africa, diverse regulatory ecosystems and heterogeneity in healthcare funding models present both opportunities for tailored market entry and challenges in harmonizing approval and distribution standards.

The Asia-Pacific region exhibits dynamic growth propelled by expanding biopharma manufacturing capacity, increasing patient awareness and progressive government incentives aimed at local innovation. However, this region also contends with variable regulatory timelines and pricing pressures influenced by national healthcare reforms. Across all regions, collaborative networks among academic institutions, contract research organizations and contract development manufacturers drive efficiency, setting the stage for cross-border partnerships and knowledge exchange that further refine strategic planning.

Profiling Leading Biopharmaceutical Innovators Driving Advancement in Anti-α4β7 Integrin Monoclonal Antibody Therapeutic Development

The competitive landscape features a cadre of prominent biopharmaceutical organizations advancing anti-α4β7 integrin monoclonal antibody programs through robust pipelines and strategic alliances. Leading players have solidified their positions by securing patents for novel molecular frameworks, forging partnerships with contract research and development firms, and investing in outcome-based access models. Their efforts are reinforced by sustained clinical development commitments, with multiple late-stage trials evaluating efficacy, safety and real-world effectiveness across diverse patient populations.

Simultaneously, emerging innovators are leveraging platform technologies to optimize antibody affinity and stability, differentiating their assets in a crowded field. Mergers and acquisitions activity underscores the value placed on these assets, as larger companies seek to augment portfolios and consolidate market share. In response, stakeholders are enhancing their intellectual property strategies, expanding specialty manufacturing networks and exploring co-development agreements to expedite clinical milestones and secure sustainable revenue streams.

Strategic Imperatives for Industry Leaders to Accelerate Growth and Optimize Commercialization of Anti-α4β7 Integrin Monoclonal Antibody Products

To capitalize on evolving market dynamics, industry leaders should adopt a strategic framework that balances innovation with operational resilience. Investing in flexible manufacturing platforms and regional production hubs can mitigate tariff and supply chain risks, while diversifying supplier networks ensures continuity of raw material access. Concurrently, implementing comprehensive health economics and outcomes research programs will strengthen value propositions and facilitate payer negotiations for outcome-based reimbursement agreements.

Clinical development strategies must prioritize patient stratification and real-world evidence generation, leveraging digital tools for remote monitoring and adherence support. Strengthening collaborations with advocacy groups and academic thought leaders will amplify educational outreach and foster patient engagement. Moreover, manufacturers should refine market access pathways by aligning pricing strategies with regional reimbursement models and exploring risk-sharing frameworks. By integrating these recommendations, industry stakeholders can drive sustainable growth and maximize the impact of anti-α4β7 integrin therapies.

Rigorous Methodological Framework Guiding the Comprehensive Analysis of Anti-α4β7 Integrin Monoclonal Antibody Market Dynamics

This analysis rests on a rigorous methodological framework designed to ensure accuracy, relevance and comprehensiveness. Primary research encompassed in-depth interviews with key opinion leaders, clinical investigators, regulatory experts and commercial strategists, providing first-hand insights into therapeutic trends and market drivers. Secondary research involved systematic review of peer-reviewed journals, regulatory filings, conference proceedings and publicly available corporate disclosures.

Data triangulation validated qualitative findings against quantitative indicators, while cross-functional workshops enabled iterative refinement of insights. Geographic and segment-specific analyses were conducted to capture regional nuances and patient journey variations. Quality assurance protocols, including peer review and consistency checks, reinforced the integrity of the report’s conclusions. By adhering to these methodological principles, the research delivers a robust, actionable guide for decision-makers navigating the anti-α4β7 integrin monoclonal antibody landscape.

Synthesizing Key Insights to Chart the Future Trajectory of Anti-α4β7 Integrin Monoclonal Antibody Therapeutic Development and Adoption

In synthesizing the findings, it is evident that anti-α4β7 integrin monoclonal antibodies are poised to redefine standards of care in inflammatory gastrointestinal disorders. The convergence of scientific innovation, strategic segmentation and adaptive regulatory environments underscores an inflection point in therapy development and commercialization. Stakeholders equipped with nuanced understanding of tariff implications, regional dynamics and competitive activities are better positioned to seize emerging opportunities and navigate complex market entry pathways.

As the field advances, continued emphasis on real-world evidence, value-based pricing and patient-centric support programs will be critical in sustaining momentum. The interplay between clinical rigor and commercial agility will determine the long-term success of these therapies. Through strategic alignment of research, manufacturing and market access initiatives, industry participants can collectively shape a new era of precision immunotherapy, delivering meaningful improvements in patient outcomes across diverse global settings.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Indication
    • Crohn's Disease
      • Colonic
      • Ileal
      • Ileocolonic
    • Indeterminate Colitis
    • Microscopic Colitis
    • Ulcerative Colitis
      • Left-Sided Colitis
      • Pancolitis
      • Proctitis
  • Administration Route
    • Intravenous Infusion
    • Subcutaneous Injection
  • Line Of Therapy
    • First Line
    • Second Line
    • Third Line And Beyond
  • Distribution Channel
    • Hospital Pharmacy
      • Inpatient Hospitals
      • Outpatient Hospitals
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
    • Specialty Pharmacy
      • Hospital Affiliated Specialty Pharmacy
      • Independent Specialty Pharmacy
  • Patient Age Group
    • Adult
    • Geriatric
    • Pediatric
  • Dosage Form
    • Autoinjector
    • Prefilled Syringe
    • Single Dose Vial
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:

  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of anti-a4ß7 integrin therapies for ulcerative colitis driven by emerging real-world evidence supporting improved remission rates
5.2. Competitive landscape intensifies as biosimilar candidates targeting a4ß7 integrin antibodies advance into phase III clinical trials
5.3. Novel subcutaneous formulations of anti-a4ß7 integrin antibodies advance to late-stage development enhancing patient convenience and adherence
5.4. Strategic collaborations between biotech and pharma firms accelerate anti-a4ß7 integrin antibody commercialization in key emerging markets
5.5. Regulatory bodies review accelerated approval pathways for next-generation anti-a4ß7 integrin monoclonal antibodies based on surrogate endpoints
5.6. Expansion of indication research for anti-a4ß7 integrin antibodies into Crohn’s disease and other immune-mediated inflammatory disorders
5.7. Pricing and reimbursement negotiations intensify as payers assess the value proposition of high-cost anti-a4ß7 integrin therapies
5.8. Technological innovations in antibody engineering optimize a4ß7 integrin binding affinity while minimizing immunogenicity risks
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Indication
8.1. Introduction
8.2. Crohn's Disease
8.2.1. Colonic
8.2.2. Ileal
8.2.3. Ileocolonic
8.3. Indeterminate Colitis
8.4. Microscopic Colitis
8.5. Ulcerative Colitis
8.5.1. Left-Sided Colitis
8.5.2. Pancolitis
8.5.3. Proctitis
9. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Administration Route
9.1. Introduction
9.2. Intravenous Infusion
9.3. Subcutaneous Injection
10. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line And Beyond
11. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.2.1. Inpatient Hospitals
11.2.2. Outpatient Hospitals
11.3. Retail Pharmacy
11.3.1. Chain Pharmacy
11.3.2. Independent Pharmacy
11.4. Specialty Pharmacy
11.4.1. Hospital Affiliated Specialty Pharmacy
11.4.2. Independent Specialty Pharmacy
12. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Patient Age Group
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Pediatric
13. Anti-a4ß7 Integrin Monoclonal Antibody Market, by Dosage Form
13.1. Introduction
13.2. Autoinjector
13.3. Prefilled Syringe
13.4. Single Dose Vial
14. Americas Anti-a4ß7 Integrin Monoclonal Antibody Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Anti-a4ß7 Integrin Monoclonal Antibody Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Anti-a4ß7 Integrin Monoclonal Antibody Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Takeda Pharmaceutical Company Limited
17.3.2. AbbVie Inc
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET: RESEARCHAI
FIGURE 28. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET: RESEARCHSTATISTICS
FIGURE 29. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET: RESEARCHCONTACTS
FIGURE 30. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COLONIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COLONIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEOCOLONIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ILEOCOLONIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDETERMINATE COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDETERMINATE COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY MICROSCOPIC COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY MICROSCOPIC COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LEFT-SIDED COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LEFT-SIDED COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PANCOLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PANCOLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PROCTITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PROCTITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INPATIENT HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INPATIENT HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY OUTPATIENT HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY OUTPATIENT HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL AFFILIATED SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL AFFILIATED SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDEPENDENT SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDEPENDENT SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 139. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 142. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 143. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 144. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 145. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 146. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 147. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 148. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 149. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 152. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 153. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 154. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 155. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 156. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 157. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 158. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 159. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 160. CANADA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 161. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 164. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 165. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 166. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 167. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 168. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 169. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 170. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 171. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 174. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 175. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 176. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 177. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 178. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 179. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 180. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 181. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 182. MEXICO ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY CROHN'S DISEASE, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY SPECIALTY PHARMACY, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 273. GERMANY ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 274. GERMANY ANTI-?4?7 INTEGRIN MONOCLONAL ANTIBODY MARKET SIZE, BY I

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Anti-α4β7 Integrin Monoclonal Antibody market report include:
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc

Related Topics

Related Reports

CD47 Antigen Inhibitors - Pipeline Insight, 2025 - Product Image

CD47 Antigen Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA - Product Image

2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA

  • Report
  • 84 Pages
  • Global
From
Anti-integrin Agents Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 - Product Image

Anti-integrin Agents Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

  • Report
  • 120 Pages
  • Global
From
Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2025 - Product Image

Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Integrin Alpha 4 Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type - Product Image

Integrin Alpha 4 Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

  • Report
  • 91 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.